Noxopharm reveals encouraging new pancreatic cancer preclinical study data

Noxopharm CEO Dr Gisela Mautner speaks with Proactive's Andrew Scott about encouraging new preclinical data from its long-term collaboration with UNSW Sydney. Recent results highlight a potential treatment for pancreatic cancer. Results from the study which involves Noxopharm’s novel preclinical drug, showed tumour cells decreased by up to 85% and barrier cells by up to 87%. The study will be followed by more tests on the therapeutic efficacy of CRO-67, which has potential to improve patient outcomes via a ‘dual-cell’ targeting activity.
#Noxopharm #pancreaticcancertherapy #asx #proactiveaustralia